GSTM1 and Tangier disease: Hence, there is a need for an alternative treatment capable of alleviating symptoms associated with transfusion dependence and therefore iron overload [25]. HU and thalidomide, identified as potent Hb inducers, have been subjected to numerous trials, all of which have demonstrated their effectiveness in increasing Hb levels and reducing transfusion requirements in patients with TDT, whether administered individually or in combination [17,23-27].